Their findings suggest that BAFF neutralization ameliorates colitis by mitigating inflammation and suppressing NF-κB and NLRP3-related signaling pathways, thus offering a promising therapeutic target for IBD treatment. The gene discussed is TNFSF13B; the disease is inflammatory bowel disease.